breast cancer now
breast cancer now Company Information
Group Structure
View All
Industry
Other human health activities
Registered Address
6th floor, the white chapel buil, 10 whitechapel high street, london, E1 8QS
Website
www.breastcancernow.orgbreast cancer now Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER NOW at £68.3m based on a Turnover of £57.5m and 1.19x industry multiple (adjusted for size and gross margin).
breast cancer now Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER NOW at £36.4m based on an EBITDA of £4.2m and a 8.77x industry multiple (adjusted for size and gross margin).
breast cancer now Estimated Valuation
Pomanda estimates the enterprise value of BREAST CANCER NOW at £118.6m based on Net Assets of £48.3m and 2.46x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Breast Cancer Now Overview
Breast Cancer Now is a live company located in london, E1 8QS with a Companies House number of 09347608. It operates in the other human health activities sector, SIC Code 86900. Founded in December 2014, it's largest shareholder is unknown. Breast Cancer Now is a established, large sized company, Pomanda has estimated its turnover at £57.5m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Breast Cancer Now Health Check
Pomanda's financial health check has awarded Breast Cancer Now a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
4 Weak
Size
annual sales of £57.5m, make it larger than the average company (£724.6k)
£57.5m - Breast Cancer Now
£724.6k - Industry AVG
Growth
3 year (CAGR) sales growth of 10%, show it is growing at a faster rate (7.9%)
10% - Breast Cancer Now
7.9% - Industry AVG
Production
with a gross margin of 38.6%, this company has a comparable cost of product (38.6%)
38.6% - Breast Cancer Now
38.6% - Industry AVG
Profitability
an operating margin of 5.8% make it as profitable than the average company (5.3%)
5.8% - Breast Cancer Now
5.3% - Industry AVG
Employees
with 360 employees, this is above the industry average (18)
360 - Breast Cancer Now
18 - Industry AVG
Pay Structure
on an average salary of £44.5k, the company has a higher pay structure (£27.4k)
£44.5k - Breast Cancer Now
£27.4k - Industry AVG
Efficiency
resulting in sales per employee of £159.6k, this is more efficient (£48.3k)
£159.6k - Breast Cancer Now
£48.3k - Industry AVG
Debtor Days
it gets paid by customers after 32 days, this is later than average (20 days)
32 days - Breast Cancer Now
20 days - Industry AVG
Creditor Days
its suppliers are paid after 25 days, this is slower than average (16 days)
25 days - Breast Cancer Now
16 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Breast Cancer Now
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 70 weeks, this is less cash available to meet short term requirements (111 weeks)
70 weeks - Breast Cancer Now
111 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 28.4%, this is a higher level of debt than the average (24.2%)
28.4% - Breast Cancer Now
24.2% - Industry AVG
BREAST CANCER NOW financials
Breast Cancer Now's latest turnover from July 2024 is £57.5 million and the company has net assets of £48.3 million. According to their latest financial statements, Breast Cancer Now has 360 employees and maintains cash reserves of £17.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 57,459,000 | 49,579,000 | 66,884,000 | 43,022,000 | 40,037,000 | 41,781,000 | 30,503,000 | 28,318,000 | 27,616,000 | 26,997,000 | 28,493,000 |
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | 3,175,000 | -4,115,000 | 22,771,000 | 10,334,000 | -255,000 | 2,905,000 | -376,000 | -1,591,000 | -4,086,000 | -6,352,000 | -5,434,000 |
| Tax | |||||||||||
| Profit After Tax | 3,175,000 | -4,115,000 | 22,771,000 | 10,334,000 | -255,000 | 2,905,000 | -376,000 | -1,591,000 | -4,086,000 | -6,352,000 | -5,434,000 |
| Dividends Paid | |||||||||||
| Retained Profit | 3,175,000 | -4,115,000 | 22,771,000 | 10,334,000 | -255,000 | 2,905,000 | -376,000 | -1,591,000 | -4,086,000 | -6,352,000 | -5,434,000 |
| Employee Costs | 16,024,000 | 13,931,000 | 12,527,000 | 10,764,000 | 14,211,000 | 9,709,000 | 6,789,000 | 6,415,000 | 6,864,000 | 8,983,000 | 8,243,000 |
| Number Of Employees | 360 | 330 | 294 | 269 | 311 | 225 | 160 | 156 | 166 | 207 | 208 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 507,000 | 389,000 | 587,000 | 624,000 | 1,000,000 | 1,418,000 | 781,000 | 982,000 | 1,162,000 | 1,150,000 | 624,000 |
| Intangible Assets | 2,311,000 | 2,066,000 | 998,000 | 1,117,000 | 643,000 | 373,000 | 335,000 | 292,000 | 279,000 | 191,000 | |
| Investments & Other | 19,196,000 | 19,693,000 | 19,958,000 | 10,413,000 | 8,522,000 | 15,279,000 | 15,727,000 | 17,577,000 | 16,201,000 | 21,005,000 | 16,789,000 |
| Debtors (Due After 1 year) | 11,107,000 | 12,732,000 | 15,040,000 | ||||||||
| Total Fixed Assets | 33,121,000 | 34,880,000 | 36,583,000 | 12,154,000 | 10,165,000 | 17,070,000 | 16,843,000 | 18,851,000 | 17,642,000 | 22,346,000 | 17,413,000 |
| Stock & work in progress | 14,000 | 25,000 | |||||||||
| Trade Debtors | 5,134,000 | 3,639,000 | 4,000,000 | 6,106,000 | 672,000 | 3,690,000 | 579,000 | 1,113,000 | 881,000 | 1,494,000 | 1,363,000 |
| Group Debtors | |||||||||||
| Misc Debtors | 11,583,000 | 10,647,000 | 9,571,000 | 5,962,000 | 6,640,000 | 8,857,000 | 5,982,000 | 5,754,000 | 6,071,000 | 2,203,000 | 3,959,000 |
| Cash | 17,574,000 | 15,817,000 | 19,460,000 | 24,071,000 | 22,086,000 | 12,027,000 | 7,882,000 | 4,968,000 | 5,921,000 | 5,870,000 | 18,369,000 |
| misc current assets | 32,000 | 49,000 | 77,000 | 110,000 | 701,000 | ||||||
| total current assets | 34,291,000 | 30,103,000 | 33,031,000 | 36,139,000 | 29,412,000 | 24,603,000 | 14,475,000 | 11,884,000 | 12,950,000 | 9,677,000 | 24,392,000 |
| total assets | 67,412,000 | 64,983,000 | 69,614,000 | 48,293,000 | 39,577,000 | 41,673,000 | 31,318,000 | 30,735,000 | 30,592,000 | 32,023,000 | 41,805,000 |
| Bank overdraft | |||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 2,446,000 | 1,435,000 | 1,896,000 | 1,708,000 | 218,000 | 1,787,000 | 760,000 | 943,000 | 691,000 | 1,092,000 | 1,774,000 |
| Group/Directors Accounts | |||||||||||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 10,455,000 | 12,898,000 | 14,312,000 | 15,758,000 | 15,703,000 | 16,014,000 | 11,726,000 | 12,375,000 | 12,251,000 | 9,719,000 | 12,210,000 |
| total current liabilities | 12,901,000 | 14,333,000 | 16,208,000 | 17,466,000 | 15,921,000 | 17,801,000 | 12,486,000 | 13,318,000 | 12,942,000 | 10,811,000 | 13,984,000 |
| loans | |||||||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | 5,798,000 | 5,105,000 | 3,860,000 | 3,992,000 | 7,039,000 | 6,864,000 | 8,054,000 | 6,671,000 | 6,629,000 | 6,642,000 | 7,670,000 |
| provisions | 448,000 | 455,000 | 341,000 | 401,000 | 517,000 | 653,000 | |||||
| total long term liabilities | 6,246,000 | 5,560,000 | 4,201,000 | 4,393,000 | 7,556,000 | 7,517,000 | 8,054,000 | 6,671,000 | 6,629,000 | 6,642,000 | 7,670,000 |
| total liabilities | 19,147,000 | 19,893,000 | 20,409,000 | 21,859,000 | 23,477,000 | 25,318,000 | 20,540,000 | 19,989,000 | 19,571,000 | 17,453,000 | 21,654,000 |
| net assets | 48,265,000 | 45,090,000 | 49,205,000 | 26,434,000 | 16,100,000 | 16,355,000 | 10,778,000 | 10,746,000 | 11,021,000 | 14,570,000 | 20,151,000 |
| total shareholders funds | 48,265,000 | 45,090,000 | 49,205,000 | 26,434,000 | 16,100,000 | 16,355,000 | 10,778,000 | 10,746,000 | 11,021,000 | 14,570,000 | 20,151,000 |
| Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 245,000 | 256,000 | 414,000 | 359,000 | 450,000 | 393,000 | 309,000 | 259,000 | 373,000 | 401,000 | |
| Amortisation | 555,000 | 269,000 | 249,000 | 110,000 | 159,000 | 130,000 | 124,000 | 74,000 | |||
| Tax | |||||||||||
| Stock | -14,000 | -11,000 | 25,000 | ||||||||
| Debtors | 806,000 | -1,593,000 | 16,543,000 | 4,756,000 | -5,235,000 | 5,986,000 | -306,000 | -85,000 | 3,255,000 | -1,625,000 | 5,322,000 |
| Creditors | 1,011,000 | -461,000 | 188,000 | 1,490,000 | -1,569,000 | 1,027,000 | -183,000 | 252,000 | -401,000 | -682,000 | 1,774,000 |
| Accruals and Deferred Income | -2,443,000 | -1,414,000 | -1,446,000 | 55,000 | -311,000 | 4,288,000 | -649,000 | 124,000 | 2,532,000 | -2,491,000 | 12,210,000 |
| Deferred Taxes & Provisions | -7,000 | 114,000 | -60,000 | -116,000 | -136,000 | 653,000 | |||||
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | 2,254,000 | -192,000 | 5,417,000 | ||||||||
| Change in Investments | -497,000 | -265,000 | 9,545,000 | 1,891,000 | -6,757,000 | -448,000 | -1,850,000 | 1,376,000 | -4,804,000 | 4,216,000 | 16,789,000 |
| cash flow from investments | 497,000 | 265,000 | -9,545,000 | -1,891,000 | 6,757,000 | 448,000 | 4,104,000 | -1,568,000 | 10,221,000 | -4,216,000 | -16,789,000 |
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | |||||||||||
| Other Short Term Loans | |||||||||||
| Long term loans | |||||||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | 693,000 | 1,245,000 | -132,000 | -3,047,000 | 175,000 | -1,190,000 | 1,383,000 | 42,000 | -13,000 | -1,028,000 | 7,670,000 |
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | 693,000 | 1,245,000 | -132,000 | -3,047,000 | 175,000 | 1,482,000 | 1,791,000 | 1,358,000 | 524,000 | -257,000 | 33,255,000 |
| cash and cash equivalents | |||||||||||
| cash | 1,757,000 | -3,643,000 | -4,611,000 | 1,985,000 | 10,059,000 | 4,145,000 | 2,914,000 | -953,000 | 51,000 | -12,499,000 | 18,369,000 |
| overdraft | |||||||||||
| change in cash | 1,757,000 | -3,643,000 | -4,611,000 | 1,985,000 | 10,059,000 | 4,145,000 | 2,914,000 | -953,000 | 51,000 | -12,499,000 | 18,369,000 |
breast cancer now Credit Report and Business Information
Breast Cancer Now Competitor Analysis
Perform a competitor analysis for breast cancer now by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in E 1 area or any other competitors across 12 key performance metrics.
breast cancer now Ownership
BREAST CANCER NOW group structure
Breast Cancer Now has 5 subsidiary companies.
Ultimate parent company
BREAST CANCER NOW
09347608
5 subsidiaries
breast cancer now directors
Breast Cancer Now currently has 14 directors. The longest serving directors include Ms Sonia Gayle (Apr 2019) and Mrs Barbara Brown (Apr 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Sonia Gayle | England | 63 years | Apr 2019 | - | Director |
| Mrs Barbara Brown | England | 58 years | Apr 2019 | - | Director |
| Mr Andrew Moore | 67 years | Apr 2019 | - | Director | |
| Mrs Jill Thompson | England | 60 years | Apr 2019 | - | Director |
| Dr Nisha Sharma | England | 52 years | Jul 2021 | - | Director |
| Professor Ingunn Holen | England | 61 years | Jul 2021 | - | Director |
| Professor Mitch Dowsett | England | 72 years | Jul 2021 | - | Director |
| Dr Georgette Oni | England | 47 years | May 2022 | - | Director |
| Dr Andreas Makris | England | 64 years | May 2022 | - | Director |
| Mrs Claire Ryan | England | 56 years | Sep 2022 | - | Director |
P&L
July 2024turnover
57.5m
+16%
operating profit
3.4m
0%
gross margin
38.7%
-1.42%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
July 2024net assets
48.3m
+0.07%
total assets
67.4m
+0.04%
cash
17.6m
+0.11%
net assets
Total assets minus all liabilities
breast cancer now company details
company number
09347608
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
December 2014
age
11
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
July 2024
previous names
breast cancer care and breast cancer now (February 2020)
breast cancer now (April 2019)
See moreaccountant
-
auditor
CROWE UK LLP
address
6th floor, the white chapel buil, 10 whitechapel high street, london, E1 8QS
Bank
BARCLAYS BANK PLC
Legal Advisor
RUSSEL COOKE
breast cancer now Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to breast cancer now.
breast cancer now Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BREAST CANCER NOW. This can take several minutes, an email will notify you when this has completed.
breast cancer now Companies House Filings - See Documents
| date | description | view/download |
|---|
